AHCA Logo

Behavioral Health Medication Management Resources

Psychotherapeutic Medication Legislation

Pursuant to statute F.S. 409.912(13): The Agency may not pay for psychotropic medication prescribed for a child in the Medicaid program without the express and informed consent of the child’s parent or legal guardian. The physician shall document the consent in the child’s medical record and provide the pharmacy with a signed attestation of this documentation with the prescription. The express and informed consent or court authorization for a prescription of psychotropic medication for a child in the custody of the Department of Children and Families shall be obtained pursuant to s. 39.407.

Consent Forms

Florida Center for Behavioral Health Improvements and Solutions

  • 2019-2020 Florida Best Practice Psychotherapeutic Medication Guidelines for Adults
  • 2018-2019 Florida Best Practice Psychotherapeutic Medication Guidelines for Children and Adolescents
  • 2019 Autism Spectrum Disorder & Intellectual Developmental Disorder: Florida Best Practice Psychotherapeutic Medication Recommendations for Target Symptoms
  • 2020 Monitoring Physical Health Guidelines of Psychotherapeutic Medications in Adults and Children: An Integrated Approach

Florida Behavioral Health Collaborative Pediatric Hotline (1-866-487-9507)

The Florida Behavioral Health Collaborative Pediatric Hotline offers a coaching experience between child and adolescent psychiatrists and pediatric primary care providers. Consultations are available to all providers regardless of insurance carrier caring for children/youth up to 21 years old.

Substance Abuse and Mental Health Services Administration, SAMHSA  

  • Steps to become a Buprenorphine Waivered Practitioner (updated)
  • Opioid Treatment Providers Resources and Information
  • Medication Assisted Treatment (MAT) Services Locators
  • Buprenorphine Pharmacy Lookup Tool

American Society of Addiction Medicine (ASAM)

  • National Practice Guidelines developed for the treatment of opioid use disorder and the prevention of opioid overdose-related deaths.
  • ASAM Treatment of Opioid Use Disorder Course
  • Waiver Information and Application Process
  • FAQ on New HHS Buprenorphine Practice Guidelines

Adverse Event Reporting

Consumers and health professionals are encouraged to report problems (adverse reactions) with behavioral health medications to the Food and Drug Administration (FDA). Please click on the link below to access the FDA Safety page and report a problem.

http://www.fda.gov/Safety/MedWatch/HowToReport/ucm085568.htm